Friday, December 21, 2018 9:33:57 PM
Only Trials Results Matter
Honestly, the postings on this message board cannot in any substantive way control what either retail or institutional investors decide to pay for shares of AVXL. For the few who follow the postings of the regulars here, our pronouncements are understood to be, at best, tangential.
The only thing that really matters will be the ability of Anavex Life Sciences Corp to sell any of their proposed drugs somewhere in the world. Presently not possible. No regulatory authorization for such; awaiting affirmative clinical trials results. Results will appear in 2019, confirming and denying any and all of the corporate and science assessment postings that have appeared here.
I fully expect results to be very positive; for all three central nervous system conditions being tested: Rett syndrome (on the basis of very positive mice-with-Rett trials); Parkinson’s dementia; and Alzheimer’s dementia, because of the ability of Anavex 2-73 to restore normalized neuron homeostasis (as shown in a multitude of murine studies).
But, will all of that happen? A number of frequent posters claim that it can’t or won’t. I and others believe it will. But until sufficient clinical results appear, contentions of Anavex success or failure are merely clinically-unsubstantiated conjectures.
Henceforth, my postings should be distant and infrequent, at best; until results appear. Until then, I will have little to usefully contribute. I have no compulsion, interest, or purpose in trying to persuade readers to my very positive outlook. We are all grown-ups here, making our own personal investment decisions.
My best wishes to all.
Indeed, let the trials begin!
...the trials have to proceed,....
Honestly, the postings on this message board cannot in any substantive way control what either retail or institutional investors decide to pay for shares of AVXL. For the few who follow the postings of the regulars here, our pronouncements are understood to be, at best, tangential.
The only thing that really matters will be the ability of Anavex Life Sciences Corp to sell any of their proposed drugs somewhere in the world. Presently not possible. No regulatory authorization for such; awaiting affirmative clinical trials results. Results will appear in 2019, confirming and denying any and all of the corporate and science assessment postings that have appeared here.
I fully expect results to be very positive; for all three central nervous system conditions being tested: Rett syndrome (on the basis of very positive mice-with-Rett trials); Parkinson’s dementia; and Alzheimer’s dementia, because of the ability of Anavex 2-73 to restore normalized neuron homeostasis (as shown in a multitude of murine studies).
But, will all of that happen? A number of frequent posters claim that it can’t or won’t. I and others believe it will. But until sufficient clinical results appear, contentions of Anavex success or failure are merely clinically-unsubstantiated conjectures.
Henceforth, my postings should be distant and infrequent, at best; until results appear. Until then, I will have little to usefully contribute. I have no compulsion, interest, or purpose in trying to persuade readers to my very positive outlook. We are all grown-ups here, making our own personal investment decisions.
My best wishes to all.
Indeed, let the trials begin!
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
